Mylan (MYL)

Q2 2011 Earnings Call

July 27, 2011 10:30 am ET


Heather Bresch - President and Director

Robert Coury - Chairman, Chief Executive Officer and Chairman of Executive Committee

John Sheehan - Chief Financial Officer and Executive Vice President

Kris King - Executive Director of Investor Relations


David Risinger - Morgan Stanley

John Boris - Citigroup Inc

Ronny Gal - Sanford C. Bernstein & Co., Inc.

Michael Faerm - Crédit Suisse AG

Elliot Wilbur - Needham & Company, LLC

Timothy Chiang - CRT Capital Group LLC

Christopher Schott - JP Morgan Chase & Co

Gregory Gilbert - BofA Merrill Lynch

Shibani Malhotra - RBC Capital Markets, LLC

Marc Goodman - UBS Investment Bank

Louise Chen - Collins Stewart LLC



Welcome to Mylan's Second Quarter Earnings Conference Call and Webcast. Hosting the call today for Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1:30 p.m. Eastern Time. The dial-in number is (855) 859-2056 and enter pin number 82698144. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King. You may begin.

Kris King

Thank you, Melissa. Good morning, everyone. Joining me for today's call are Mylan's Chairman and Chief Executive Officer, Robert J. Coury; President, Heather Bresch; and Executive Vice President and Chief Financial Officer, John Sheehan.

During today's call, including the Q&A, we will be making forward-looking statements including those relating to our anticipated business levels, our future earnings, our planned activities, our anticipated growth, and other expectations and targets for future periods. Note that these statements are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Because these statements are forward-looking, they inherently involve risks and uncertainties, and accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risk factors set forth in our report on Form 10-Q for the period ended March 31, 2011, and in our other SEC filings. You can access our Form 10-Q and other SEC filings through the SEC website at, and we strongly encourage you to do so.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids